Britain has finalized a U.S.-UK pharmaceutical trade deal, granting tariff-free access for UK-made medicines to the United States in exchange for paying higher prices for new U.S. medicines.
The agreement, concluded as part of a broader U.S.-UK trade pact signed last year, mandates Washington to implement a zero tariff on British pharmaceutical exports for at least three years. The British government stated the deal would make Britain the only country with tariff-free access for medicines to the U.S. market.
British Business and Trade Secretary Peter Kyle stated on Thursday that the partnership would support Britain’s world-leading pharmaceutical sector while safeguarding high-skilled jobs, adding that it demonstrated the strength of the U.S.-British economic relationship.
Pharmaceuticals account for about a fifth of British goods exports to the United States by value, according to government data.
The White House and U.S. Department of Health and Human Services did not immediately respond to requests for comment.
Donald Trump's NYE party - missing kids, worrying words and famous guests
Pricing changes
The deal is anticipated to bring changes to the “appraisal framework” at NICE, the UK body assessing the cost-effectiveness of National Health Service medicines, but Thursday’s announcement did not provide details.
In December, when the outline terms of the partnership were announced, officials mentioned that the changes would result in an effective increase of around 25% in the net prices paid for some new U.S. medicines.
Britain also stated that the deal protected medical technology exports from additional tariffs and included assurances it would receive mitigations under a proposed U.S. “most favored nation” drug pricing policy, which aims to align U.S. medicine prices with those in other developed countries.
The pharmaceuticals provisions were negotiated separately from the broader U.S.-British trade deal signed by President Donald Trump and Prime Minister Keir Starmer in June 2025, with the two sides unveiling the outline terms in December.
In a separate statement on Thursday, Britain stated the deal would enable closer cooperation between its Medicines and Healthcare products Regulatory Agency and the U.S. Food and Drug Administration, including efforts toward aligning medical device regulation to help accelerate patient access to new technologies.
Zero-tariff terms tied to U.S. pricing and tariff policy
Britain and the U.S. stated in December that the agreement would ensure zero tariffs on British pharmaceutical products and medical technology in exchange for higher UK spending on medicines and changes to how new drugs are valued.
In return for Britain raising the net price it pays for new U.S. medicines, UK-made medicines, drug ingredients, and medical technology would be exempt from U.S. Section 232 sectoral tariffs and any future Section 301 country-specific tariffs.
Britain-headquartered drugmakers AstraZeneca and GSK separately secured most-favored-nation pricing agreements with the Trump administration last year, including three-year protection from potential U.S. pharmaceutical tariffs, emphasizing Washington’s broader use of tariff threats in negotiations with the sector.
Inside late mogul's luxury 'party palace' that has hit market for $6million
Following the announcement of the deal, a GSK spokesperson expressed satisfaction with its finalization, adding that it provided certainty on zero tariffs for medicines and improved the British operating environment while rewarding innovation.
The spokesperson stressed the need for rapid action on the detailed steps to achieve the improvements.
Lifestyle & Culture Editor
Read more similar news:
Comments:
comments powered by Disqus
